| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.ATHEROSCLEROSIS.2017.11.007 |
| P8608 | Fatcat ID | release_ulmrxwlayffr3alokvaxc6ioeu |
| P932 | PMC publication ID | 6392003 |
| P698 | PubMed publication ID | 29169030 |
| P50 | author | Eric Boerwinkle | Q28050857 |
| Parveen K. Garg | Q57548706 | ||
| Ron C Hoogeveen | Q60644631 | ||
| Richard A Gibbs | Q64856497 | ||
| Aaron R. Folsom | Q71098091 | ||
| Christie M. Ballantyne | Q98665268 | ||
| Faye L. Norby | Q55445198 | ||
| P2093 | author name string | Kunihiro Matsushita | |
| Megan L Grove | |||
| Pranav S Garimella | |||
| Linda M Polfus | |||
| P2860 | cites work | A new equation to estimate glomerular filtration rate | Q24651973 |
| Lipoprotein-Associated Phospholipase A 2 , Platelet-Activating Factor Acetylhydrolase, Is Expressed by Macrophages in Human and Rabbit Atherosclerotic Lesions | Q59704158 | ||
| Cardiac and pulmonary causes of dyspnoea--validation of a scoring test for clinical-epidemiological use: the Study of Men Born in 1913 | Q69421682 | ||
| A short questionnaire for the measurement of habitual physical activity in epidemiological studies | Q70501617 | ||
| Ability of the Atherosclerosis Risk in Communities (ARIC)/Baecke Questionnaire to assess leisure-time physical activity | Q70870281 | ||
| Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency | Q71329185 | ||
| Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency | Q71734585 | ||
| Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group | Q73088406 | ||
| Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study | Q28217746 | ||
| Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study) | Q28273657 | ||
| The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators | Q29614947 | ||
| Best practices and joint calling of the HumanExome BeadChip: the CHARGE Consortium | Q30418185 | ||
| Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. | Q30458108 | ||
| The reliability of the ankle-brachial index in the Atherosclerosis Risk in Communities (ARIC) study and the NHLBI Family Heart Study (FHS) | Q33234885 | ||
| Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis | Q33567912 | ||
| Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles | Q33768940 | ||
| Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies | Q33829154 | ||
| Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis | Q34361910 | ||
| Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target | Q34397742 | ||
| Coronary heart disease and genetic variants with low phospholipase A2 activity | Q35116234 | ||
| Targeted enrichment beyond the consensus coding DNA sequence exome reveals exons with higher variant densities | Q35557672 | ||
| Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies | Q35673148 | ||
| Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells | Q35822759 | ||
| Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis | Q35856590 | ||
| Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target | Q36187055 | ||
| ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascul | Q36426489 | ||
| Lipoprotein-Associated Phospholipase A2 and Incident Peripheral Arterial Disease in Older Adults: The Cardiovascular Health Study | Q36730558 | ||
| Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial | Q38424365 | ||
| Ethnic-specific prevalence of peripheral arterial disease in the United States | Q40230436 | ||
| Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. | Q40253076 | ||
| Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease in a multi-ethnic cohort: The Multi-Ethnic Study of Atherosclerosis | Q40328826 | ||
| Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern G | Q40479587 | ||
| Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. | Q40639610 | ||
| Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease | Q40868032 | ||
| Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience | Q40973059 | ||
| Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor | Q42992999 | ||
| Ethnicity and peripheral arterial disease: the San Diego Population Study | Q43825468 | ||
| Novel cardiovascular risk factors do not completely explain the higher prevalence of peripheral arterial disease among African Americans. The San Diego Population Study | Q44951726 | ||
| Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study | Q45256250 | ||
| Mortality over a period of 10 years in patients with peripheral arterial disease | Q46786119 | ||
| Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study | Q46825104 | ||
| International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis | Q46887817 | ||
| Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort | Q50643607 | ||
| Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. | Q51679983 | ||
| Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease; Edinburgh Artery Study Edinburgh Artery Study | Q56287923 | ||
| Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease | Q57243317 | ||
| P921 | main subject | atherosclerosis | Q12252367 |
| P304 | page(s) | 12-18 | |
| P577 | publication date | 2017-11-14 | |
| P1433 | published in | Atherosclerosis | Q4813570 |
| P1476 | title | Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease: Findings from The Atherosclerosis Risk in Communities study (ARIC) | |
| P478 | volume | 268 |
Search more.